Podcasts about expert perspectives

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

More options, more questions. Get clarity on patient selection and optimizing adjuvant cyclin-dependent kinase cyclin-dependent kinase (CDK)4/6 inhibitor therapy. Credit available for this activity expires: 9/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002908?ecd=bdc_podcast_libsyn_mscpedu

In this AANEM session, Chilvana Patel, MD moderates a discussion with Pushpa Narayanswami, MD, Nicholas Silvestri, MD, and Kelly Gwathmey, MD on the evolving treatment landscape in myasthenia gravis (MG). The panel reviews the use of targeted therapies in women of childbearing age with myasthenia gravis, alongside guidance for perioperative care before elective surgery. Through illustrative patient cases, the experts provide insight into practical challenges and emerging opportunities in tailoring advanced immunotherapies to individual patient needs.

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YFD865. CME credit will be available until August 26, 2026.Expert Perspectives on Novel Approaches to Therapy for ATTR Cardiac Amyloidosis In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics:  Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00) Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42) Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn's disease — Neil Morganstein, MD (17:48) Case: A man in his early 70s with metastatic cholangiocarcinoma (FGFR2 rearrangement) receives gemcitabine/oxaliplatin with durvalumab and experiences a rapid clinical decline — Kimberly Ku, MD (27:14) Case: A woman in her late 40s with Stage IV recurrent cholangiocarcinoma (FGFR2 rearrangement) receives pemigatinib — Justin Peter Favaro, MD, PhD (40:15) Case: A woman in her early 60s with HER2-positive cholangiocarcinoma develops metastatic disease during adjuvant capecitabine therapy — Dr Morganstein (46:09) CME information and select publications

Dr Haley Ellis and Dr James J Harding review actual patient cases and summarize clinical trial findings regarding the treatment of biliary tract cancers. CME information and select publications here.

Dr Haley Ellis and Dr James J Harding review actual patient cases and summarize clinical trial findings regarding the treatment of biliary tract cancers. CME information and select publications here.

Dr Haley Ellis and Dr James J Harding review actual patient cases and summarize clinical trial findings regarding the treatment of biliary tract cancers. CME information and select publications here.

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Christie M. Ballantyne, MD - At the Forefront of the Latest Developments in FCS: Expert Perspectives on Emerging Evidence

Featuring perspectives from Dr Stephen V Liu and Dr Charles Rudin, including the following topics:  Introduction (0:00) Case 1: Adjuvant Systemic Therapy? (1:15) Case 2: Lambert-Eaton Syndrome and Other Paraneoplastic Syndromes (4:16) Case 3: Small Cell Transformation of EGFR-Mutant Non-Small Cell Lung Cancer (9:54) Case 4: Trilaciclib in Extensive-Stage Disease (13:50) Comments: ASCO and Other Recent Datasets (18:05) Case 5: Short Disease-Free-Interval with Brain Metastases After Chemoradiation Therapy/Durvalumab … Lurbinectedin? (39:34) Case 6: Tarlatamab After Rapid Disease Progression on Chemotherapy/Atezolizumab (44:33) Case 7: Immune Effector Cell-Associated Neurotoxicity Syndrome on Tarlatamab with Brain Metastases (48:54) Case 8: Bispecific T-Cell Engager with Lurbinectedin on Protocol (56:38) CME information and select publications

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. CME information and select publications here.

Chilvana Patel, MD is hosting a case-based panel discussion titled "Evolving Therapeutic Horizons in Myasthenia Gravis: Expert Perspectives on Targeted Therapies - Part 1." She will engage with renowned neuromuscular specialists—Pushpa Narayanaswami, MD, Nicholas Silvestri, MD, and Kelly Gwathmey, MD—to explore real-world cases and discuss the latest advances in targeted treatment options for Myasthenia Gravis.

CME credits: 1.00 Valid until: 20-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/ Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date! =

CME credits: 1.00 Valid until: 20-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/ Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date! =

Featuring perspectives from Dr Geoffrey Y Ku and Dr Zev Wainberg, including the following topics: Introduction: ASCO Preview (0:00) HER2-Positive Gastroesophageal Cancers (19:03) Immunotherapy in HER2-Negative Advanced Gastroesophageal Cancers (36:11) Immunotherapy in Microsatellite Instability-High Gastroesophageal Cancers (44:04) CLDN18.2-Positive Advanced Gastroesophageal Cancers (51:30) CME information and select publications

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

Dr Geoffrey Y Ku from the Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Zev Wainberg from the UCLA School of Medicine discuss patient cases and summarize current treatment approaches for gastroesophageal cancer. CME information and select publications here.

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

Richard David Graham Leslie, MD, FRCP, FAoP - When Could Dysglycaemia in Adults Be Type 1 Diabetes? Expert Perspectives on Recognising and Addressing Diagnostic Complexities and Challenges

CME credits: 0.25 Valid until: 23-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-from-aua-2025-contextualizing-the-evolving-landscape-of-bladder-cancer/33076/ This online CME program features expert discussions on new research presented at AUA 2025. Drs. Neal Shore and Sarah Psutka explore emerging data on treatment strategies for high-risk BCG-naïve and BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). They also highlight advances in biomarker-directed therapies, including investigational agents targeting HER2 and FGFR alterations. The program emphasizes the clinical relevance and practical application of these findings, offering clinicians actionable insights on evolving bladder cancer care.=

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MRT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until March 30, 2026.Navigating the ADC Roadmap for Modern Gynecologic Cancer Treatment: Expert Perspectives on Personalizing Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women's Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, and Pfizer Inc. and Genmab.Disclosure information is available at the beginning of the video presentation.

Today on the Clean Power Hour, Tim Montague sits down with Eric Goodwin, Vice President of Business Development at OMCO Solar, to explore the evolution and future of solar manufacturing in the United States. From its roots as a truck bumper manufacturer in 1955 to becoming America's largest custom roll former with 13GW of annual solar racking capacity, OMCO's story exemplifies the transformation of US manufacturing in the renewable energy era.Eric shares invaluable insights into OMCO's journey from a contract manufacturer for other racking companies to developing their own innovative product line, including fixed-tilt and tracker solutions. The conversation goes deep into the impact of the Inflation Reduction Act, domestic content requirements, and how OMCO achieves 88-92% domestic content in their products. Listeners will learn about OMCO's exciting partnership with Create Energy, founded by industry pioneer Dean Solon (founder of Shoals Technologies), and their shared vision for advancing US solar manufacturing.We also discussed our upcoming exclusive webinar featuring OMCO Solar, Sunstall, and Obodo Energy on Jan 23, 1 PM Eastern, Noon Central, 11 AM Mountain, and 10 AM Pacific! Eric Goodwin and Matt Kessler from OMCO Solar, Helge Biernath, CEO of Sunstall, and John Mitman, CEO of Obodo Energy, will share their insights on handling project changes, adapting to unexpected site conditions, managing supply chain disruptions, and implementing module changes mid-installation with minimal impact. Learn from their years of successful collaboration and discover how strong partnerships can drive project success even in challenging circumstances. This webinar will showcase practical examples and strategies that have helped their teams deliver successful solar installations while minimizing change orders and project delays. Register here for the webinar.Don't miss this comprehensive discussion about one of the most critical components of utility-scale and distributed-generation solar projects.Social Media HandlesOMCO Solar WebinarEric GoodwinOMCO Support the showConnect with Tim Clean Power Hour Clean Power Hour on YouTubeTim on TwitterTim on LinkedIn Email tim@cleanpowerhour.com Review Clean Power Hour on Apple PodcastsThe Clean Power Hour is produced by the Clean Power Consulting Group and created by Tim Montague. Contact us by email: CleanPowerHour@gmail.com Corporate sponsors who share our mission to speed the energy transition are invited to check out https://www.cleanpowerhour.com/support/The Clean Power Hour is brought to you by CPS America, maker of North America's number one 3-phase string inverter, with over 6GW shipped in the US. With a focus on commercial and utility-scale solar and energy storage, the company partners with customers to provide unparalleled performance and service. The CPS America product lineup includes 3-phase string inverters from 25kW to 275kW, exceptional data communication and controls, and energy storage solutions designed for seamless integration with CPS America systems. Learn more at www.chintpowersystems.com

In the world of commercial real estate, gaining financial freedom isn't just a dream—it's an achievable goal. As discussed by host Jonathan Hayek and guest Jay Conner in this insightful episode of the Scott Paton Podcast, understanding the intricate details of raising capital, fostering meaningful relationships, and having a strategic investment approach are pivotal for success.Raising Capital for Real EstateOne of the first steps towards achieving financial freedom in commercial real estate involves raising capital. Jonathan Hayek highlights that while familiarity with real estate can be beneficial, it's not strictly necessary. Interestingly, his initial deal was made possible by borrowing $110,000 from a contact named Ryan via a self-directed IRA, and another $50,000 from a friend. This emphasizes that leveraging personal networks can be an effective strategy for securing funds.Moreover, having a proven track record can significantly attract private money lenders. Hayek himself leveraged a mix of funding sources which included private money, hard money, balance transfers from credit cards, and local banks. He stresses the importance of presenting specific deals with clear terms to potential investors rather than vague promises of future opportunities.Strategic Investment ApproachesBoth Jonathan Hayek and Jay Conner emphasize a non-aggressive approach when it comes to finding investors. Rather than chasing or begging for money, they advocate for building genuine relationships. Hayek stresses the importance of attracting investors who are confident, financially secure, and a good fit for the deal.Straightforwardly presenting investment opportunities is crucial. It promotes trust and clarity, which, in turn, can lead to successful, long-term investment partnerships. A critical takeaway from their discussion is that the quality of investors often outweighs the quantity.Growing Mindset and Overcoming Limiting BeliefsJonathan Hayek's journey from being a special education teacher and non-profit worker to a full-time real estate investor underscores the importance of personal growth and overcoming limiting beliefs. He shares how he realized the need for greater financial growth and decided to pursue bigger goals.One of Hayek's personal growth strategies involves adopting mantras like "You're Not Thinking Big Enough." He encourages listeners to challenge deeply ingrained beliefs, many of which are rooted in childhood, to achieve their true potential. This mindset shift enabled him to leave his job and fully commit to real estate, exploring non-traditional opportunities such as industrial deals.Building a Sustainable BusinessA key insight from this episode is the concept of "rightsizing" your business to fit individual, family, and lifestyle needs, as discussed by Jay Conner. Jonathan Hayek emphasizes understanding one's "why" in real estate to avoid the pervasive pressure of constant scaling driven by social media influences. Bigger isn't always better; the focus should be on creating a business that aligns with personal goals, whether it's spending more time with family or enjoying freedom.The Power of Networks and ReferralsTrust and relationships are central to raising private money. Jay Conner and Jonathan Hayek both highlight that investors essentially invest in the person, based on reliability and trustworthiness. Jonathan's network of lenders is primarily based on established relationships with friends and family, leveraging their faith in his ability to manage their investments securely.Additionally, referrals play a crucial role. By delivering successful deals, Jonathan and Jay have benefited from referrals from existing lenders, further broadening their network and enhancing their investment opportunities.Real Estate Investment StrategiesJonathan Hayek has a focused app